四价流感疫苗在6-35月龄儿童中的效力和安全性:一项全球、多季节、对照、随机III期研究
这项随机III期试验将6-35月龄流感未感染儿童分配接种四价流感疫苗(QIV)或非流感对照疫苗,QIV对任何流行株所致流感的绝对效力为54%(95%CI:37%,66%),对抗原匹配株为68%(95%CI:45%,81%),安全性与对照疫苗相当。
要点
- QIV对任何流行株所致流感的绝对效力为54%(95%CI:37%,66%)。
- QIV对抗原匹配株所致流感的绝对效力为68%(95%CI:45%,81%)。
- QIV总体安全性和反应原性与对照疫苗相当。
核心结论
- QIV初次接种耐受良好,可有效保护6-35月龄儿童免受流感侵袭。
研究设计与样本
- 随机III期试验,在三个流感季节将6-35月龄流感未感染儿童随机分配接种QIV或非流感对照疫苗,部分受试者在后续流感季节再接种QIV。
- 共1005名儿童接种QIV,995名儿童接种对照疫苗。
主要发现
- 任何流行流感株所致A/B型流感在QIV组的发生频率低于对照疫苗组。
- QIV对任何流行株所致流感的绝对效力为54%(95%CI:37%,66%),对抗原匹配株为68%(95%CI:45%,81%)。
- QIV组所有流感株的平均血凝抑制滴度在接种后升高,而对照疫苗组升高幅度极小;病毒中和试验和神经氨酸酶抑制试验结果与血凝抑制试验基本一致。
- QIV初次接种约12个月后,大多数毒株的抗体滴度仍高于接种前水平;再接种者中QIV引发强抗体应答。
- QIV总体安全性和反应原性与对照疫苗相当。
关键数值与推荐
- QIV对任何流行株所致流感的绝对效力为54%(95%CI:37%,66%)。
- QIV对抗原匹配株所致流感的绝对效力为68%(95%CI:45%,81%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Children are an important target group for influenza vaccination, but few studies have prospectively evaluated influenza vaccine efficacy (VE) in children under 3 years of age. This was a randomized Phase III trial to assess the efficacy, immunogenicity, and safety of an inactivated quadrivalent influenza vaccine (QIV) in young children (EudraCT: 2016-004904-74). METHODS: Influenza-naïve children aged 6-35 months were randomized during three influenza seasons to receive vaccination with QIV or a non-influenza control vaccine. One group of participants was revaccinated with QIV in the subsequent influenza season. The primary efficacy endpoint was the absolute VE of QIV against influenza caused by any circulating strain. Key secondary efficacy endpoints included the absolute VE of QIV against influenza due to antigenically matching strains and immunogenicity. Safety and reactogenicity were also evaluated. RESULTS: In total, 1005 children received QIV and 995 received control vaccine. Influenza A/B infection due to any circulating influenza strain occurred less frequently in children who received QIV versus children receiving a control vaccine. The absolute VE of QIV against any circulating influenza strain was 54% (95% confidence interval [CI]: 37%, 66%). The absolute VE of QIV against antigenically matching influenza strains was 68% (95% CI: 45%, 81%). Mean hemagglutination inhibition titers for all influenza strains in the QIV group increased post-vaccination, whereas increases were minimal in the control vaccine group; results from virus neutralization and neuraminidase-inhibition assays were generally consistent with the hemagglutination inhibition assay findings. Approximately 12 months after primary vaccination with QIV, antibody titers remained higher than pre-vaccination titers for most strains. In participants who were revaccinated, QIV elicited strong antibody responses. The overall safety profile and reactogenicity of QIV was comparable with control vaccine. CONCLUSION: Primary vaccination with QIV was well tolerated and effective in protecting children aged 6-35 months against influenza.
引用
- Esposito S, Nauta J, Lapini G, et al. Efficacy and safety of a quadrivalent influenza vaccine in children aged 6-35 months: A global, multiseasonal, controlled, randomized Phase III study. Vaccine. 2022. PMID: 35315323. doi:10.1016/j.vaccine.2022.02.088
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。